

Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines

Eva-Maria Duerr,^{1,3} Yusuke Mizukami,^{1,4} Kentaro Moriichi,¹ Manish Gala,¹ Won-Seok Jo,¹ Hirotohi Kikuchi,¹ Ramnik J. Xavier,^{1,2} and Daniel C. Chung¹

¹Gastrointestinal Unit, ²Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; ³Department of Gastroenterology, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany; and ⁴Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

Submitted 7 February 2011; accepted in final form 16 February 2012

Duerr EM, Mizukami Y, Moriichi K, Gala M, Jo WS, Kikuchi H, Xavier RJ, Chung DC. Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines. *Am J Physiol Gastrointest Liver Physiol* 302: G1223–G1230, 2012. First published March 1, 2012; doi:10.1152/ajpgi.00047.2011.—Activating mutations in the *KRAS* oncogene are common in colorectal cancer. However, the complete spectrum of *KRAS* targets that mediate its tumorigenic effect has not yet been fully delineated. We identified bone morphogenetic protein 4 (Bmp4), a transforming growth factor- β family member that regulates development and tissue homeostasis, as a new target of *KRAS*. In SW480, Hela, and 293 cells, oncogenic *KRAS*^{V12} downregulated *BMP4* RNA levels, a *BMP4* promoter luciferase construct, and Bmp4 protein levels. The MEK inhibitor PD98059 but not the phosphatidylinositol 3-kinase inhibitor LY294002 blocked this downregulation of *BMP4*. To identify the region of the *BMP4* promoter that mediated this regulation by *KRAS*, serial 5'-deletions of the promoter were generated. An inhibitory region was identified between -3,285 and -3,258 bp in the *BMP4* promoter. In summary, oncogenic *KRAS* can downregulate Bmp4 through a transcriptional pathway that depends on ERK. These findings point to a unique link between two pathways that are frequently altered in colon cancer.

bone morphogenetic protein 4; GATA2; colon cancer; extracellular signal-regulated kinase; phosphatidylinositol 3-kinase

KRAS, A GDP/GTP BINDING PROTEIN that functions as a key intracellular signal transducer, is one of the most frequently activated oncogenes in human cancer. As many as 17–25% of all tumors harbor a *KRAS* mutation (18). It plays a particularly important role in the pathogenesis of colon cancer, where mutations are identified in up to 50% of cases. In its active, GTP-bound state, *KRAS* signals through multiple downstream pathways including the RAF/MEK, MAPK, JNK, and phosphatidylinositol 3-kinase pathways (4, 6, 21, 23) and thereby regulates target genes that promote cell growth and survival. However, the complete spectrum of targets that mediate the oncogenic effects of *KRAS* has not yet been fully delineated.

In an attempt to identify novel genes regulated by oncogenic *KRAS* in colon cancer, we utilized a cDNA microarray approach and previously identified bone morphogenetic protein 4 (Bmp4), a member of the transforming growth factor- β (TGF- β) family. Alterations in TGF- β signaling are known to play an important role in the pathogenesis of many human cancers, including colon cancer (28, 32). Although most studies have focused on the role of TGF- β in malignancy, there is growing evidence that the BMP subfamily also plays an im-

portant tumor suppressive role (17). Bmp4 binds to its type II receptor and recruits a type I receptor (BMPRI1A and BMPRI1B). After heterodimerization, the type II receptor phosphorylates and activates the type I receptor, resulting in serine-threonine kinase activity and concomitant phosphorylation of the signal transducer molecules Smads-1/5/8. The phosphorylated Smads-1/5/8 then heterodimerize with Smad4 and translocate to the nucleus, where they regulate the expression of Bmp4 target genes.

Recently, it has been demonstrated that germline mutations in either *BMPRI1A* or *SMAD4* result in the inherited cancer predisposition syndrome juvenile polyposis (11–12, 37), indicating a role for the BMP pathway in the pathogenesis of intestinal polyps and tumors. This was confirmed in a mouse model, where inhibition of BMP signaling resulted in the formation of numerous ectopic crypts, mimicking the juvenile polyposis syndrome (7). In addition, BMP signaling controls duplication of intestinal stem cells through suppression of Wnt- β -catenin signaling, thereby preventing crypt fission and the subsequent increase in crypt number (9). Furthermore, BMPs exhibit tumor-suppressive properties in human colon cancer cells (1, 24). However, Bmp4 has not yet been linked to *KRAS*.

In the present study, we describe a novel interaction between *KRAS* and Bmp4 in colon cancer. Oncogenic *KRAS* can transcriptionally downregulate Bmp4 expression, and this is mediated through the ERK signaling pathway. In the *BMP4* promoter, an inhibitory region was identified that was responsive to *KRAS*. These findings point to a unique link between two pathways that are frequently disrupted in colon cancer.

EXPERIMENTAL PROCEDURES

Cell culture. 293T and Hela cells were maintained in DMEM supplemented with 10% FBS and penicillin/streptomycin. The human colon cancer cell line SW480 stably transfected with a small interfering (si)RNA against mutant *KRAS*^{V12} (SW480^{siKrasV12}) or a mock siRNA (SW480^{siControl}; Ref. 14) was maintained in DMEM supplemented with 10% FBS, penicillin/streptomycin, and 2 μ g/ml puromycin. Cells were treated with 20 μ M PD98059 (Calbiochem) and 50 μ M LY290042 (Calbiochem) for 12–24 h.

DNA microarrays. RNA was isolated from SW480^{siControl} and SW480^{siKrasV12} cells utilizing the RNeasy mini prep kit per manufacturer's instructions (Qiagen, Valencia, CA). RNA quality control, target preparation, and array hybridization and scanning were performed per recommended specifications (Asuragen, Austin, TX). Genechip PrimeView human arrays were utilized (Affymetrix, Santa Clara, CA). CEL files were analyzed utilizing R/Bioconductor package, oneChannelGUI. Briefly, normalization of expression values was performed utilizing the "Expresso" option, selecting "RMA" as the background correction, "quantiles" as normalization, "pmonly" as the

Address for reprint requests and other correspondence: D. C. Chung, GRJ 825, Massachusetts General Hospital, Boston, MA 02114 (e-mail: dchung@partners.org).

PM correction, and "MAS" as the expression. Probes were filtered with IQR settings of 0.25. *P* values were calculated using a two-tailed Student's *t*-test. Microarray data have been submitted to Gene Expression Omnibus (GSE35663).

Plasmids and constructs. The phr-GFP-KRAS^{V12}, phr-GFP-KRAS^{D12}, phr-GFP-KRAS^{D13}, phr-GFP-KRAS^{wt}, and kinase-mutant ERK1/2 constructs have been described previously (14, 16, 31). Empty phr-GFP and pcDNA3 plasmids were used as controls, respectively. The human Bmp4-promoter luciferase plasmid 3.36-kb Bmp4-luc was generated by PCR amplifying the *BMP4* promoter 1 region using the human RP112526II clone (Invitrogen) as a template and cloning the PCR product into pGL3basic vector using the unique restriction enzyme sites NHE1 and XHO1. The construct was confirmed by DNA sequencing. Deletion constructs were generated by digesting 3.36-kb Bmp4-luc with Psi and XHO1 to generate the 3.17-kb Bmp4-luc plasmid, with Kpn1 and Xho1 to generate the 2.1-kb Bmp4-luc plasmid, with AvrII and Nhe1 to generate the 1.7-kb Bmp4-luc plasmid and with SpeI and Nhe1 to generate the 0.46-kb Bmp4-luc plasmid. Site-directed mutants were generated using the Quick-Change protocol (Stratagene) and the mutagenic primers 5'-GGAATTAAGGGCTACTGCGCTTATAGGATTATCTTTTCAC and 5'-GTGAAAAGATAATCCTATAAGCGCAGTAGCCCTTAATCC. The introduced mutations were confirmed by DNA sequencing. The human Bmp4-promoter 2-luciferase plasmid was generated by PCR amplifying the *BMP4* promoter 2 region using the human RP112526II clone (Invitrogen) as a template and cloning the PCR product into pGL3basic vector using the unique restriction enzyme sites HindIII and XHO1. The construct was confirmed by direct sequencing. The full length *BMP4* promoter luciferase plasmid, containing both promoter 1 and promoter 2, was generated by subcloning the 3.36-kb Bmp4 fragment into Bmp4-Prom2-luc. pRLnull plasmid was used as for assaying transfection efficiency.

Transfections. Transient transfections of plasmid DNA was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. SW480^{siKrasV12} and SW480^{siControl} cells were seeded in 12-well dishes to reach 50% confluency the day of transfection. The 0.8 ug of promoter plasmids were cotransfected with 50 ng pRL-null plasmid and harvested 24 h after transfection. Luciferase assays were performed using the Dual Luciferase Kit (Promega) on a luminometer (Monolight 3010; Pharmingen). 293T and Hela cells were seeded in 6 well dishes to reach 60% confluency the day of transfection. Two micrograms of expression plasmid were transfected, and RNA was harvested 24–48 h after transfection.

RNA analysis. RNA was extracted using RNeasy mini kit (Qiagen) and quantitative reverse transcription PCR was performed using SuperScript III Platinum Two-Step qRT-PCR kit (Invitrogen). The 18S rRNA served as an endogenous control. Primer sequences for Bmp4 and 18S are available upon request. PCR cycles were 2 min at 95°C, followed by 40 cycles with annealing temperature of 55–58°C. A fluorogenic SYBR Green and MJ research detection system were used for real time quantification. Relative mRNA expression was calculated using the parameter threshold cycle (*C_T*) values. ΔC_T was the difference in the *C_T* values derived from the specific gene being assayed and the 18S rRNA. $\Delta\Delta C_T$ represented the difference between the paired samples, as calculated by the formula ΔC_T of a sample $-\Delta C_T$ of a reference. The amount of target was normalized to 18S, and the reference was calculated as $2^{-\Delta\Delta C_T}$.

ELISA. Bmp4 protein concentration was assayed utilizing the Quantikine human Bmp4 kit (R&D Systems) following the manufacturer's recommendations. SW480^{siControl} and SW480^{siKrasV12} cells were seeded into 6-cm dishes to reach 80% confluence the next day. Serum starvation was performed for 24 h. Supernatant was collected, centrifuged, and used undiluted for ELISA.

Western blot analysis. Cells were lysed in chilled lysis buffer (Cell Signaling) supplemented with proteinase inhibitor (PSC; Roche). Then, 15–20 ug protein lysate were resolved on 4–12% NuPAGE Bis-Tris polyacrylamid gels (Invitrogen) and transferred to polyvi-

nylidene difluoride membranes (Millipore). Nuclear extracts were isolated using NPER kit (Pierce). The blots were probed with KRAS (Santa Cruz; 1:1,000), pERK and total ERK (Cell Signaling; 1:1,000), pSMAD1/5/8 and SMAD1 (Cell Signaling; 1:1,000), and β -actin (Sigma; 1:3,000) antibodies. Immunoreactive proteins were visualized using Western Lighting Chemiluminescence Reagent Plus (Perkin Elmer Life Sciences).

BMP4 mRNA decay assay. SW480^{siControl} and SW480^{siKrasV12} cells were treated with 5 ug/ml actinomycin D. RNA was harvested after 0, 1, 2, 4, 8, and 12 h and transcribed into cDNA. Quantitative (q)RT-PCR was performed with Bmp4 and 18S primers as described.

Methylation assays. SW480^{siControl} and SW480^{siKrasV12} cells were seeded in 60-mm dishes. Twenty-four hours later, 2 μ M 5-azacytidine (Sigma) were added to the medium. Cells were treated for 4 days with daily replacement of 5-azacytidine. RNA was extracted 4 days after initiation of treatment and qRT-PCR performed as described.

Bisulfite sequencing. DNA from SW480^{siControl} and SW480^{siKrasV12} cells was extracted utilizing blood and cell culture kit (Qiagen). One microgram DNA of each cell line was diluted in 21 μ l Tris-EDTA (TE) buffer. Four microliters of a 2-M NaOH solution were added and samples were incubated at 50°C for 20 min. After incubation, DNA was mixed with low-melting agarose, and beads were formed by dropping 10 μ l of DNA mixture into cold mineral oil. DNA-containing agarose beads were incubated with 2.5 M sodium metabisulfite and 125 mM hydroquinone at 50°C for 4 h. Beads were washed four times with TE. After being washed, beads were desulphonated with 0.3 M NaOH for 15 min at room temperature. After being desulphonated, beads were again washed twice with TE and twice with water. Washed beads were used as template in a nested PCR. Primer sequences are available upon request. PCR products were purified and sequenced.

Acetylation assays. SW480^{siControl} and SW480^{siKrasV12} cells were seeded in sixwell dishes and treated with 50 nM trichostatin A for 48 h. RNA was extracted and qRT-PCR performed as described.

Cell growth assays. Then, 1×10^5 SW480^{siControl} and SW480^{siKrasV12} cells were seeded into sixwell dishes. Cells were treated for 5 days with 2 ug inhibitory anti-Bmp4 antibody (R&D Systems) or mock treated and counted each day using Trypan blue (Invitrogen) and a hemacytometer (Fisher Scientific).

EMSA. Nuclear extracts were prepared utilizing NE-PER nuclear extraction reagent (Pierce). Sequences of the *BMP4* promoter between 3,361 and 3,171 bp were divided into five fragments and utilized as oligonucleotide probes (Table 1). The 5'-ends of the oligonucleotides were labeled with biotin during synthesis, and complementary oligonucleotides were annealed to generate double-stranded fragments. EMSA was performed using LightShift chemiluminescent kit (Pierce) according to the manufacturer's protocol. Briefly, 5 μ g of nuclear extracts were incubated with 20 fmol of biotinylated oligonucleotides in binding buffer including 50 ng/ μ l poly(dI-dC), 0.05% Nonidet P-40, 2.5% glycerol, 5 mM MgCl₂, and 2 mM EDTA, and the reaction mix was loaded onto 6% DNA retardation gels (Invitrogen). DNA-protein complexes were transferred onto nylon membranes (Roche Applied Science), and the mobility shift was detected using a streptavidin-horseradish peroxidase conjugate and a chemiluminescent substrate. Specificity of shifts was confirmed by utilizing 200-fold molar excess of unbiotinylated oligonucleotides as a specific competitor. Mutagenesis was performed to further define the elements responsible for the specific shifts obtained, as described in Table 1.

RESULTS

Downregulation of Bmp4 by mutant KRAS. In SW480 colon cancer cells, the endogenous *KRAS* gene harbors an oncogenic G12V point mutation. Stable transfection of a specific siRNA against this mutant *KRAS* resulted in a 90% reduction of *KRAS* protein expression (Fig. 1). Accompanying this reduction in *KRAS* protein levels was a marked reduction of ERK1 and

Table 1. Sequences of oligonucleotide probes used for gel-shift assays

Oligonucleotides	Sequence
1	5'-GAATTCCTTCGGTAGCTTCACCAGACACCTAATTGGCCAA
2	5'-GGCCAAGAAGGTTTGAAGACCTGATGTGGTTCTTAATGGGGATGG
3	5'-GATGGGAATTAAGGGCTACTGTATCTATAGGATTATCTTTTCACT
3A	5'-GATGGGAATTAAGGGCTACTGTATCTA
3B	5'-TACTGTATCTATAGGATTATCTTTTCACT
4	5'-CTTTTCACTTGCATAGACCTATTTGGTGTGTTTCAGGGC
5	5'-GGGCATAGTGATACTATAATTGCCATATTTAACAGTTTATAAAG
Mut1	5'-AGCAAAAAGGTTAAGGGCTACTGTATCTA
Mut2	5'-GATGGGAACCGGAAATCACTGTATCTA
Mut3	5'-GATGGGAATTAAGGGCTGTCAAGCTCG

ERK2 phosphorylation (Fig. 1). cDNA microarray studies of RNA isolated from stably transfected SW480^{siControl} and SW480^{siKrasV12} cells indicated that Bmp4 gene expression was twofold higher in cells in which mutant K-ras was knocked down ($P < 0.05$). qRT-PCR was performed to verify this result. There was a 7.7-fold increase in *BMP4* mRNA expression in cells in which K-ras was knocked down (Fig. 2A). As a complementary study, we examined another colon cancer cell line with an endogenous wild-type K-ras gene (HT29). Introduction of a mutant K-ras expression suppressed BMP4 levels 52%. Of note, no such suppression was seen when a wild-type K-ras expression vector was transfected. To determine whether this was a cell-type-specific effect, 293T and Hela cells were transfected with a mutant *KRAS*^{V12} expression plasmid and *BMP4* mRNA levels were measured. qRT-PCR revealed an ~50% reduction of *BMP4* mRNA expression in these cells (Fig. 2, B and C), indicating that mutant *KRAS* can downregulate Bmp4 in a cell-type independent manner. In contrast, overexpression of wild-type *KRAS* in 293 cells led to only a 12% reduction in Bmp4 levels, indicating this was effect was *KRAS* genotype-specific. Finally, a significant downregulation of Bmp4 protein levels was confirmed by ELISA in SW480^{siControl} cells (Fig. 2D). Thus mutant *KRAS* can downregulate Bmp4 expression.




Fig. 1. Knockdown of K-ras blocks activation of ERK. Two different cell clones stably transfected with a small interfering (siRNA) against mutant K-rasV12 in SW480 colon cancer cells (SW480^{siKrasV12}) or stably transfected with a control siRNA (SW480^{siControl}) were analyzed for K-ras expression by Western blotting. Silencing of K-ras disrupts activation of ERK 1 and 2, shown as a reduction in phosphorylation (p-ERK1 and p-ERK2).

Silencing of KRAS inhibits cell growth in a Bmp4-dependent manner. To verify that Bmp4 has a functional role in colon cancer cells, assays for Smad phosphorylation were performed. Downregulation of Bmp4 by mutant *KRAS* in SW480^{siControl} cells reduced the phosphorylation levels of Smad1/5/8, which are key mediators of the intracellular Bmp4 signaling pathway (Fig. 3A). In vitro cell growth assays were then performed to define the effects of *KRAS* silencing. Stable knockdown of mutant *KRAS* was associated with a significant, twofold decrease in cell number after 5 days (Fig. 3B). Furthermore, treatment of SW480^{siKrasV12} cells with a neutralizing Bmp4 antibody over a 5-day period resulted in a marked increase in cell proliferation, whereas it did not affect the proliferation rate of SW480^{siControl} cells (Fig. 3B). Silencing of *KRAS* can therefore reduce cellular proliferation in a Bmp4-dependent manner.

KRAS downregulates Bmp4 through ERK. We next sought to identify which *KRAS* effector pathway may mediate this downregulation of Bmp4. The role of the ERK pathway was examined utilizing the specific inhibitor PD98059. Twenty micromoles of PD98059 increased *BMP4* mRNA expression 5.1-fold in SW480^{siControl} cells ($P = 0.007$; Fig. 4). However, inhibition of the phosphatidylinositol 3-kinase pathway with LY294002 failed to induce *BMP4* mRNA levels in SW480^{siControl} cells (Fig. 4). Of note, although inhibition of the ERK pathway strongly induced *BMP4*, it did not reach the peak induction observed with knockdown of *KRAS*, suggesting that the ERK pathway is a key but not sole mediator of the downregulation of Bmp4 by *KRAS*.

KRAS regulates Bmp4 expression through transcriptional mechanisms. To determine more specifically how *KRAS* regulates *BMP4* mRNA levels, mRNA decay assays were performed to determine whether *KRAS* altered *BMP4* mRNA stability. No difference in the half-life of Bmp4 was seen in SW480^{siControl} and SW480^{siKrasV12} cells (data not shown). To determine whether *KRAS* regulated Bmp4 expression through epigenetic mechanisms, we examined the acetylation and methylation status of the *BMP4* gene. The *BMP4* promoter is GC-rich and harbors several CpG islands. However, treatment with either the histone deacetylase inhibitor trichostatin A or the demethylating agent 5-azacytidine did not result in any significant changes in *BMP4* mRNA levels in SW480^{siControl} or SW480^{siKrasV12} cells (data not shown). Furthermore, DNA bisulfite-sequencing of the CpG island closest to the transcriptional start site of the *BMP4* promoter did not reveal any methylated CpG residues within this island (data not shown).




Fig. 2. Mutant K-rasV12 can downregulate bone morphogenetic protein 4 (Bmp4). **A**: quantitative real-time PCR demonstrated a decrease in Bmp4 mRNA expression in SW480^{siControl} cell lines. Bmp4 mRNA expression normalized to SW480^{siKrasV12}. **B** and **C**: HeLa and 293T cells were transiently transfected with phr-GFP-K-rasV12 or empty control vector. Bmp4 mRNA expression is downregulated ~2-fold upon expression of mutant K-ras, as measured by quantitative RT-PCR. **D**: Bmp4 protein concentration is significantly lower in SW480^{siControl} cells compared with SW480^{siKrasV12} cells, as assessed by ELISA.

We then sought to determine whether KRAS regulates Bmp4 expression more directly through transcriptional mechanisms. The *BMP4* gene contains two promoters that are separated by the first exon and are transcribed in a cell type- and differentiation-dependent manner (34). Because it is not known which promoter is active in SW480 cells, three different promoter constructs, spanning 3.36 kb of the first promoter (3.36-kb Bmp4-luc), 2.1 kb of the second promoter (2.1-kb Bmp4-luc), or spanning both promoters (5.5-kb Bmp4-luc), were introduced into SW480^{siControl} and SW480^{siKrasV12} cells. Only the 3.36-kb Bmp4-luc construct showed activity in these cells, indicating that in SW480 cells *BMP4* is under the control of the first promoter (data not shown). Furthermore, the levels of BMP4 were twofold higher in SW480^{siKrasV12} cells compared with SW480^{siControl} cells that do not express mutant KRAS (Fig. 5A), suggesting that mutant KRAS regulates Bmp4 expression through transcriptional mechanisms.

To confirm the role of ERK in the regulation of *BMP4* gene transcription, the 3.36-kb Bmp4-luc promoter construct was cotransfected with a dominant-negative ERK plasmid (dnERK). Consistent with the effects of PD98059 on endogenous mRNA levels, dnERK enhanced *BMP4* promoter activity 2.7-fold in SW480^{siControl} cells but only 1.7-fold in SW480^{siKrasV12} cells (Fig. 5, B and C). Thus KRAS appears to downregulate *BMP4* through transcriptional mechanisms and the ERK effector pathway is an important mediator.

Identification of a regulatory region of the BMP4 promoter responsive to mutant KRAS. To identify regions of the *BMP4* promoter that mediate its repression by mutant KRAS, we performed serial 5'-deletions. A significant induction of *BMP4* promoter activity was observed in SW480^{siControl} cells when the first 190 base pairs of the promoter construct were deleted (Fig. 6A), whereas there was only a slight reduction in promoter activity in SW480^{siKrasV12} cells (Fig. 6B). This 190-bp region appeared to contain a regulatory element that repressed transcription, as further deletions did not enhance this induction significantly.

Identification of a critical regulatory element responsive to mutant KRAS. To further characterize the regulatory element in the *BMP4* promoter between -3,361 and -3,171 bp that is responsive to KRAS, EMSAs were performed. The 190-bp region was divided into five fragments that were utilized as probes for EMSAs (Table 1). Nuclear extracts were isolated from SW480^{siControl} and SW480^{siKrasV12} cells and incubated with the biotinylated probes. Several band shifts of differing intensity were observed in these experimental conditions, but we focused on a band shift that was almost completely absent using nuclear extracts from SW480^{siKrasV12} cells when incubated with oligonucleotide 3 (Fig. 7A). The specificity of the shift band was confirmed utilizing a 200-fold molar excess of unbiotinylated probe (Fig. 7B).




Fig. 3. Bmp4 signaling is intact in SW480 cells and can negatively regulate cell growth. *A*: mutant K-rasV12 results in decreased phosphorylation of the Bmp4 effector proteins Smad1/5/8. *B*: Cell growth assays were performed on SW480^{si}control and SW480^{si}KrasV12 cells that were treated with 2 μ g/ml neutralizing Bmp4 antibody or mock treated. Cells were counted each day for 5 days. Shown are the mean cell numbers of 2 independent experiments.

To further narrow the regulatory region, the 40-bp probe comprising oligonucleotide 3 was divided into two smaller oligonucleotides (probes 3A and 3B), and additional EMSAs were performed. A shifted band was readily detectable in nuclear extracts from SW480^{si}control cells that were incubated with oligonucleotide 3A (Fig. 7C) but was barely detectable when incubated with oligonucleotide 3B (data not shown). Treatment with the ERK inhibitor PD98059 resulted in a loss of the shifted band (Fig. 7D). Taken together, a regulatory element responsive to KRAS and ERK lies between $-3,285$ and $-3,258$ bp of the *BMP4* promoter.




Fig. 4. K-ras can downregulate Bmp4 through ERK activation. SW480^{si}control and SW480^{si}KrasV12 cells were treated with an ERK inhibitor (20 μ M PD98059), a phosphatidylinositol 3-kinase inhibitor (50 μ M LY290042), or mock control (DMSO) for 24 h and Bmp4 mRNA levels were determined by quantitative RT-PCR. Inhibition of ERK resulted in a 5-fold induction of Bmp4 expression in SW480^{si}control cells.




Fig. 5. K-ras downregulates Bmp4 through transcriptional mechanisms in an ERK dependent manner. *A*: SW480^{si}control and SW480^{si}KrasV12 cells were transfected with the 3.36-kb Bmp4-luc reporter construct and luciferase activity was measured. Cotransfection with a dnERK plasmid or control vector (empty) was performed, and induction of Bmp4 luciferase activity was seen in SW480^{si}control (*B*) but not SW480^{si}KrasV12 (*C*) cells. Mean values of 3 independent transfections are shown.

Transcription factor binding site analyses did not reveal any likely candidates for a transcriptional repressor that recognized DNA sequences within these 28 bp. Therefore, EMSAs were performed with 3 additional biotinylated oligonucleotides in which the first 9 bp, the second 9 bp, or the third 10 bp were mutated ("mut1," "mut2," and "mut3," respectively). Only when nuclear extracts of SW480^{si}control cells were incubated with oligonucleotide "mut3" did the specific shifted band disappear (Fig. 7E), suggesting that the key regulatory element is located within these 10 bp. The bands obtained with the "full-length" probe 3 compared with the shorter probe 3A (and its mutants mut1, mut2, and mut3) differ, and this likely reflects differences in DNA-protein interactions due to differing flanking DNA sequences. There are three potential transcription factor-binding sites for GATA1, GATA2, and PLZF in this short promoter fragment. qRT-PCR and Western Blot analyses revealed that of these three transcription factors, only GATA2 was expressed in SW480 cells (data not shown). However, when a promoter construct that contained a specific mutation for the GATA2-binding sequence was tested, no difference was seen between SW480^{si}KrasV12 and SW480^{si}control cells (data not shown). Furthermore, silencing of GATA2 with a siRNA did not significantly increase *BMP4* mRNA in SW480^{si}control cells.




Fig. 6. K-ras-responsive element in the Bmp4 promoter is identified between 3.36 and 3.17 kb. The 5'-serial deletion constructs of the human Bmp4 promoter were generated and are schematically illustrated. Locations of the transcription start sites are indicated by the arrows. SW480^{si}control (white bars, A) and SW480^{si}KrasV12 cells (black bars, B) were transiently transfected and luciferase activity measured 24 h later as described in MATERIALS AND METHODS. Values were normalized to the activity of the full-length 3.36-kb reporter fragment in each cell line, respectively.

DISCUSSION

BMPs were first identified as regulators of bone formation in adults (33), but they also play an important role in the embryonic development of multiple organs, including the nervous system, musculature, skeleton, skin, hair, teeth, kidney, lung, and the intestinal tract (10, 20). Furthermore, there is growing evidence that BMP signaling is a key regulator of tumorigenesis. The role of BMP signaling in cancer is likely to be cell type and tissue specific. BMP signaling can inhibit proliferation of breast, prostate, gastric, and colon cancer cells (2–3, 30, 35). Specifically, signaling through Bmp2 in colon cancer results in growth inhibition (2, 8). Thus far Bmp4 has not been carefully evaluated in colon cancer pathogenesis, despite the fact that it is perhaps the best understood of all Bmp family members. The regulation of Bmp4 ligand activity has been described, and specific inhibitors such as noggin, chordin and follistatin have been identified (13, 27, 38). However, insights into the regulation of Bmp4 gene expression are lacking.

BMP4 is a novel target that is downregulated by oncogenic KRAS. A recent report using rat intestinal epithelial cells also demonstrated a dramatic reduction in BMP4 gene expression by oncogenic HRAS, consistent with the present results (15). This study suggested that HRAS regulation of BMP4 may be mediated through AU-rich element motifs that control mRNA stability. However, we did not observe any differences in mRNA stability of Bmp4 in cells that expressed oncogenic KRAS.

BMP4 mRNA levels may not always correlate with secreted Bmp4 protein levels, as there is evidence that production of TGF- β superfamily members can be controlled during post-translational processing and secretion (20). However, the current studies demonstrate downregulation of Bmp4 both at the levels of mRNA and protein by KRAS. Furthermore, the functional activity of Bmp4 was verified through altered phosphorylation patterns of the downstream intracellular effectors Smad1/5/8. A limitation of the current study is that reduced levels of Bmp4 have not yet been demonstrated in human tumors with KRAS mutations.

KRAS can signal through various effector pathways, and we have demonstrated that oncogenic KRAS downregulates Bmp4 expression through MAPK/ERK signaling. This is particularly intriguing in light of previous reports that demonstrated an inhibitory effect on BMP signaling by ERK through the phosphorylation of SMAD1 in its linker region (19). In colon cancer cell lines, activation of ERK can prevent the growth inhibitory effects of BMP2/Smad signaling, potentially through this mechanism proposed by Kretzschmar et al. (19). Thus ERK may regulate BMP signaling on multiple levels. The effects of Bmp4 are classically mediated through SMAD4 pathways, but SMAD4-independent mechanisms have been described and these instead depend on ERK activation (29, 36). However, the role of these SMAD4-independent pathways in the suppression of tumor growth has yet to be defined.




Fig. 7. Identification of a critical regulatory element responsive to mutant K-ras. **A**: sequences between 3.36 and 3.17 kb in the *Bmp4* promoter were divided into 5 fragments (probes 1–5) and EMSAs were performed. Nuclear extracts of SW480^{siControl} (c) and SW480^{siKrasV12} (kd) were utilized. *Specific shift obtained in SW480^{siControl} cells by probe 3. **B**: 200-fold molar excess of unlabeled probe 3 was used as a specific competitor (sc) to confirm specificity. **C**: specific shift was also observed in SW480^{siControl} cells incubated with probe 3A, spanning the region 3,285–3258 bp of the *Bmp4* promoter. **D**: treatment of SW480^{siControl} cells with 20 μ M PD98059 disrupts the binding of the critical element to the *Bmp4* promoter. **E**: 3 different probes were generated that contain mutations of the first 10 bp (mut1), second 10 bp (mut2), and third 10 bp (mut3) of probe 3A. Specific shift (*) was lost in SW480^{siControl} cells (c) incubated with probe mut3.

Epigenetic processes including DNA methylation and histone modification are now recognized as critical events for regulation of gene expression in mammalian cells, and oncogenic *KRAS* has been implicated in both processes. It can repress RECK expression via histone deacetylation (5) and regulate DNA methylation via the expression of DNMT1 (DNA methyltransferase 1), resulting in decreased expression of uPA (urokinase-type plasminogen activator 1) and Fas (22, 25–26). In addition, the *BMP4* promoter is GC-rich and a target for DNA methylation. However, we were unable to identify any epigenetic alterations that may mediate the downregulation of *Bmp4* expression by *KRAS*.

Rather, oncogenic *KRAS* directly suppressed *BMP4* promoter activity. A novel Ras-responsive region between –3,268 and –3,258 bp of the *BMP4* promoter was identified containing a putative repressive element. Transcription factor binding site analysis revealed three potential transcription factors, namely PLZF, GATA1, and GATA2. Of these, only GATA2 is expressed in SW480 cells. However, further analysis demonstrated that GATA2 is not likely to be involved in the *KRAS*-mediated downregulation of *Bmp4*. Rather, there appears to be a new transcriptional repressor that has yet to be identified.

This relationship between *KRAS* and *Bmp4* is likely to be broadly relevant. Oncogenic *KRAS* can downregulate *BMP4* gene expression in many different tissues (colon, kidney, cervix), indicating that this effect is not tissue specific. Furthermore, this effect does not appear to be limited to the *KRAS*^{V12} mutation, as overexpression of *KRAS*^{D12} or *KRAS*^{D13} mutants in 293T cells also downregulated *BMP4* mRNA to the same extent as the *KRAS*^{V12} mutation (data not shown).

Taken together, we present a novel mechanism for the regulation of *BMP4* gene expression and provide evidence for cross talk between *KRAS* and BMP signaling in colon cancer cells that amplifies the effects on cellular proliferation. Oncogenic *KRAS* transcriptionally repressed *BMP4* gene expression via the ERK pathway, and a novel transcriptional repressor appears to mediate this unique effect.

GRANTS

E.-M. Duerr was the recipient of a research grant from the German Research Foundation (Deutsche Forschungsgemeinschaft). This work was supported in part by National Cancer Institute Grant CA-92594 (to D. C. Chung).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS

Author contributions: E.-M.D. and D.C.C. conception and design of research; E.-M.D., Y.M., K.M., W.-S.J., H.K., and R.J.X. performed experiments; E.-M.D. prepared figures; E.-M.D. drafted manuscript; Y.M., K.M., M.G., H.K., R.J.X., and D.C.C. analyzed data; K.M., M.G., R.J.X., and D.C.C. interpreted results of experiments; M.G. and D.C.C. approved final version of manuscript; D.C.C. edited and revised manuscript.

REFERENCES

1. Beck SE, Jung BH, Del Rosario E, Gomez J, Carethers JM. BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK. *Cell Signal* 19: 1465–1472, 2007.
2. Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY, Carethers JM. Bone morphogenetic protein signaling and growth suppression in colon cancer. *Am J Physiol Gastrointest Liver Physiol* 291: G135–G145, 2006.
3. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. *J Cell Biochem* 91: 151–160, 2004.
4. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. *Genes Cancer* 2: 261–274, 2011.
5. Chang HC, Liu LT, Hung WC. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. *Cell Signal* 16: 675–679, 2004.
6. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. *Biochem J* 318: 729–747, 1996.
7. Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, Clevers H. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. *Science* 303: 1684–1686, 2004.
8. Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. *Gastroenterology* 126: 111–121, 2004.
9. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet* 36: 1117–1121, 2004.
10. Hogan BL. Bone morphogenetic proteins in development. *Curr Opin Genet Dev* 6: 432–438, 1996.
11. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. *Nat Genet* 28: 184–187, 2001.
12. Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. *Science* 280: 1086–1088, 1998.
13. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early *Xenopus* embryo. *Proc Natl Acad Sci USA* 95: 9337–9342, 1998.
14. Jo WS, Mizukami Y, Duerr EM, Zukerberg LR, Chung DC. Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. *Cancer Biol Ther* 4: 1361–1366, 2005.
15. Kanies CL, Smith JJ, Kis C, Schmidt C, Levy S, Khabar KS, Morrow J, Deane N, Dixon DA, Beauchamp RD. Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. *Mol Cancer Res* 6: 1124–1136, 2008.
16. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B, Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. *Curr Biol* 12: 253–265, 2002.
17. Kitisin K, Saha T, Blake T, Golestaneh N, Deng M, Kim C, Tang Y, Shetty K, Mishra B, Mishra L. Tgf-Beta signaling in development. *Sci STKE* 2007: cm1, 2007.
18. Kranenburg O. The KRAS oncogene: past, present, and future. *Biochim Biophys Acta* 1756: 81–82, 2005.
19. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. *Nature* 389: 618–622, 1997.
20. Leong LM, Brickell PM. Bone morphogenetic protein-4. *Int J Biochem Cell Biol* 28: 1293–1296, 1996.
21. Lim L, Manser E, Leung T, Hall C. Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. *Eur J Biochem* 242: 171–185, 1996.
22. MacLeod AR, Rouleau J, Szyf M. Regulation of DNA methylation by the Ras signaling pathway. *J Biol Chem* 270: 11327–11337, 1995.
23. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. *Science* 260: 1658–1661, 1993.
24. Nishanian TG, Kim JS, Foxworth A, Waldman T. Suppression of tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4 in human cancer cells. *Cancer Biol Ther* 3: 667–675, 2004.
25. Pakneshan P, Szyf M, Rabbani SA. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. *Carcinogenesis* 26: 557–564, 2005.
26. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. *EMBO J* 18: 1824–1831, 1999.
27. Piccolo S, Sasai Y, Lu B, De Robertis EM. Dorsoventral patterning in *Xenopus*: inhibition of ventral signals by direct binding of chordin to BMP-4. *Cell* 86: 589–598, 1996.
28. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. *Adv Cancer Res* 83: 1–54, 2001.
29. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY, Iafraite AJ, Zukerberg LR, Chung DC. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. *Gastroenterology* 138: 1406–1417, 2010.
30. Pouliot F, Labrie C. Role of Smad1 and Smad4 proteins in the induction of p21WAF1, Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. *J Endocrinol* 172: 187–198, 2002.
31. Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, Cobb MH. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. *J Biol Chem* 268: 5097–5106, 1993.
32. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. *Nat Rev Cancer* 3: 807–821, 2003.
33. Urist MR, Mikulski A, Lietze A. Solubilized and insolubilized bone morphogenetic protein. *Proc Natl Acad Sci USA* 76: 1828–1832, 1979.
34. Van den Wijngaert A, Pijpers MA, Joosten PH, Roelofs JM, Van Zoelen EJ, Olijve W. Functional characterization of two promoters in the human bone morphogenetic protein-4 gene. *J Bone Miner Res* 14: 1432–1441, 1999.
35. Wen XZ, Miyake S, Akiyama Y, Yuasa Y. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. *Biochem Biophys Res Commun* 316: 100–106, 2004.
36. Zhou Q, Heinke J, Vargas A, Winnik S, Krauss T, Bode C, Patterson C, Moser M. ERK signaling is a central regulator for BMP-4 dependent capillary sprouting. *Cardiovasc Res* 76: 390–399, 2007.
37. Zhou XP, Woodford-Richens K, Lehtonen R, Kurose K, Aldred M, Hampel H, Launonen V, Virta S, Pilarski R, Salovaara R, Bodmer WF, Conrad BA, Dunlop M, Hodgson SV, Iwama T, Jarvinen H, Kellokumpu I, Kim JC, Leggett B, Markie D, Mecklin JP, Neale K, Phillips R, Piris J, Rozen P, Houlston RS, Aaltonen LA, Tomlinson IP, Eng C. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. *Am J Hum Genet* 69: 704–711, 2001.
38. Zimmerman LB, De Jesus-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. *Cell* 86: 599–606, 1996.